Skip to content

The Effect of Channa Striata and Curcuma Supplementation on Nutritional Status, Interleukin-6 Levels, and Quality of Life in Patients With Breast Cancer.

The Effect of Channa Striata and Curcuma Supplementation on Nutritional Status, Interleukin-6 Levels, and Quality of Life in Patients With Breast Cancer.

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07722156
Acronym
CCBreast
Enrollment
76
Registered
2026-07-23
Start date
2026-08-01
Completion date
2027-01-31
Last updated
2026-07-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Keywords

Breast cancer; Channa striata; Curcuma; Nutritional status; Interleukin-6 (IL-6); Quality of life; Nutritional supplementation; Inflammation., Breast cancer, Channa striata Curcuma, Interleukin-6, Quality of life

Brief summary

Breast cancer is frequently accompanied by chronic inflammation, malnutrition, and reduced quality of life, all of which may compromise treatment response and clinical outcomes. Nutritional interventions with immunomodulatory and anti-inflammatory properties have the potential to improve these conditions. Channa striata is rich in high-quality protein, albumin, and essential amino acids that support nutritional recovery and tissue repair, while Curcuma contains curcumin, a bioactive compound with well-established anti-inflammatory and antioxidant effects. This study aims to evaluate the effect of combined Channa striata and Curcuma supplementation on nutritional status, serum interleukin-6 (IL-6) levels, and quality of life in patients with breast cancer undergoing treatment. The findings are expected to provide evidence for the use of this nutritional supplementation as a complementary strategy to improve clinical outcomes, reduce systemic inflammation, and enhance the overall well-being of breast cancer patients.

Interventions

DIETARY_SUPPLEMENTchanna striata and curcuma

Participants in the intervention group received oral supplementation consisting of 5 g of Channa striata and 250 mg of Curcuma daily for one month, while participants in the control group received a maltodextrin placebo daily for the same duration.

DIETARY_SUPPLEMENTMaltodextrin (Placebo)

Participants in the control group received a placebo consisting of maltodextrin daily for one month.

Sponsors

DINA KEUMALA SARI
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
FEMALE
Healthy volunteers
No

Inclusion criteria

* Female patients with breast cancer aged ≥18 years who were undergoing chemotherapy. * Patients with a body mass index (BMI) of 18-29 kg/m². * Patients currently receiving chemotherapy for breast cancer. * Patients with serum albumin levels of 2.0-3.5 g/dL. * Patients who were able to consume oral food and were willing to participate in the study by providing written informed consent.

Exclusion criteria

* Patients with chronic kidney disease, renal failure, or kidney infection. * Patients with a known allergy to fish or Channa striata (snakehead fish) albumin-derived products. * Patients receiving other protein or amino acid supplements during the study period. * Patients who were non-compliant or discontinued the intervention before completion of the study.

Design outcomes

Primary

MeasureTime frameDescription
Nutritional statusbaseline post intervention 4 weeksThis study evaluated changes in BMI, following one month of Channa striata and Curcuma supplementation.

Secondary

MeasureTime frameDescription
interleukin - 6Baseline and 1 month after interventionChange in serum interleukin-6 (IL-6) concentration from baseline to 1 month after daily supplementation with Channa striata and Curcuma in patients with breast cancer undergoing chemotherapy

Countries

Indonesia

Contacts

CONTACTDamayanti Tridah Ayu
damayantitridahayu@gmail.com628116816444

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 24, 2026